Comparative Pharmacology
Head-to-head clinical analysis: OPCON A versus PHENERGAN VC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: OPCON A versus PHENERGAN VC.
OPCON-A vs PHENERGAN VC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Synthetic vasopressin analog; stimulates V1 receptors on vascular smooth muscle causing vasoconstriction, and V2 receptors in renal collecting ducts increasing water reabsorption.
Phenergan VC is a combination of promethazine (a phenothiazine derivative with antihistaminic, sedative, antiemetic, and anticholinergic effects) and phenylephrine (a sympathomimetic amine that acts as a decongestant via alpha-1 adrenergic receptor agonism). Promethazine antagonizes H1 receptors, thereby suppressing allergic reactions and motion sickness. Phenylephrine causes vasoconstriction in the nasal mucosa, reducing congestion.
0.1% ophthalmic solution: 1 drop in the affected eye(s) every 3-4 hours as needed for redness relief.
10-20 mL orally every 4-6 hours as needed; each 5 mL contains 6.25 mg promethazine HCl and 5 mg phenylephrine HCl.
None Documented
None Documented
Terminal elimination half-life is approximately 2-4 hours in healthy adults; may be prolonged in renal impairment.
9-16 hours; prolonged in hepatic impairment.
Primarily renal excretion of unchanged drug and metabolites; about 70-80% of the dose eliminated via urine within 24 hours, with 10-20% fecal elimination.
Renal: 70-80% as metabolites; biliary/fecal: 20-30%.
Category C
Category C
Ophthalmic Antihistamine/Decongestant Combination
Antihistamine/Decongestant Combination